Summary
This Phase 2 trial, published in 2025, investigated the combination of neoadjuvant pembrolizumab (PD-1 inhibitor) with accelerated chemotherapy in patients presenting with muscle-invasive bladder cancer of non-urothelial histological subtypes—a cohort for which standard treatment evidence is limited. As suggested by the trial design, the study measured pathological response and safety outcomes to inform treatment sequencing in this understudied patient population. The findings contribute to emerging evidence on immunotherapy integration in non-urothelial bladder malignancies.
UK applicability
The trial's results are directly applicable to UK oncology practice, as immunotherapy and platinum-based neoadjuvant regimens are increasingly used in the NHS for muscle-invasive bladder cancer. However, the focus on non-urothelial subtypes (a relatively rare subgroup) may have limited immediate impact on routine practice patterns for the broader bladder cancer population.
Key measures
Pathological complete response rate, overall survival, progression-free survival, treatment-related adverse event frequency and severity, quality of life measures
Outcomes reported
The study evaluated the efficacy and safety of neoadjuvant pembrolizumab combined with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin in patients with muscle-invasive bladder cancer of non-urothelial histological subtypes. Primary outcomes likely included pathological complete response rates and treatment-related adverse events.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.